Marshall Wace’s ADC Therapeutics ADCT Stock Holding History

Marshall Wace’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-45,479	Closed	-$171K	–	3113
2026 Q1	$171K	Buy	+45,479	New	+$179K	﹤0.01%	2815
2025 Q4	–	Sell	-159,993	Closed	-$640K	–	2910
2025 Q3	$640K	Buy	+159,993	New	+$504K	﹤0.01%	2135
2024 Q2	–	Sell	-243,243	Closed	-$1.09M	–	2493
2024 Q1	$1.09M	Buy	243,243 +221,395	+1,013%	+$817K	﹤0.01%	1618
2023 Q4	$36.3K	Sell	21,848 -416,825	-95%	-$385K	﹤0.01%	2086
2023 Q3	$395K	Buy	438,673 +73,615	+20%	+$97.9K	﹤0.01%	1793
2023 Q2	$785K	Buy	365,058 +207,379	+132%	+$466K	﹤0.01%	1825
2023 Q1	$307K	Buy	+157,679	New	+$582K	﹤0.01%	2287
2021 Q1	–	Sell	-59,567	Closed	-$1.91M	–	2416
2020 Q4	$1.91M	Sell	59,567 -136,085	-70%	-$4.46M	0.01%	970
2020 Q3	$6.46M	Buy	+195,652	New	+$8.47M	0.04%	432

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace's ADCT Position: Q2 2026 in Review

Marshall Wace sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 45,479 shares — an estimated $171K sold.

Marshall Wace first reported a position in ADCT in Q3 2020 and held it in 9 quarters. The position peaked at $6.46M in Q3 2020. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Marshall Wace reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 45,479 ADC Therapeutics shares in Q2 2026, an estimated $171K.
Marshall Wace first reported a position in ADC Therapeutics in Q3 2020 and held it in 9 quarters.
Marshall Wace's ADC Therapeutics position peaked at $6.46M in Q3 2020.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.